- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02482324
Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers
A Phase I, Randomized, Open-Labeled Pharmacokinetic Study of ALZT-OP1 in Normal Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-labeled, cross-over design, pharmacokinetic study, where 24 subjects will be randomly assigned to receive treatment regimen A-B or B-A on two consecutive days of dosing.
Two dosing groups are planned for the study :
- Group 1 (n=12)
- Group 2 (n=12)
Each group will be admitted to the Phase I Unit the evening before dosing and will initiate dosing the next morning for 2-days of consecutive treatment (A-B, or B-A). Both groups will undergo identical study related procedures, except those subjects that consent to CSF collection on Day 1 of dosing.
Dose regimen A consists of a single inhaled oral dose of ALZT-OP1a via dry powder inhaler + a single oral tablet dose of ALZT-OP1b.
Dose regimen B consists of two oral inhaled doses of ALZT-OP1a, not more than 2 minutes apart, via dry powder inhaler + two oral tablet doses of ALZT-OP1b.
Plasma Collection, All Subjects (n=24) 1 mL blood samples will be collected at T: 0, 5, 10, 15, 30, 1 hr, 2 hr, 4 hr, and 6 hours, following ALZT-OP1 administration (Days 1 and 2).
CSF Collection, Sub-group (n=12) A sub-group of 12 subjects will be consented for CSF collection.
1 mL of CSF will be collected at T: 0, 5 min, 30 min, 2 hr, and 4 hours, following ALZT-OP1 administration (Day 1 only).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami Lakes, Florida, United States, 33014
- Panax Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provide a signed written informed consent;
- Age 55-75 inclusive;
- ECG within normal limits;
- Body mass index (BMI) ≥ 18 kg/m2 and ≤ 30 kg/m2;
- Negative urine drug screen for selected drugs of abuse at screening;
- Negative for hepatitis and HIV at screening;
- Good general health, as determined by medical history, physical examination, and clinical laboratory testing;
- Willingness to stay in the unit overnight for the duration of the study;
- Consent for CSF collection (for those in CSF group).
Exclusion Criteria:
- Current smokers, or ex-smokers with a remote history (> 100 pack/year);
- Clinically significant medical conditions;
- History of ECG abnormalities;
- Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14 days prior to dosing;
- Signs of active pulmonary infection or other pulmonary inflammatory conditions, even in absence of febrile episodes, in the last 14 days;
- History or presence of disease in the kidneys and/or heart, lungs, liver, gastrointestinal tract, endocrine organs or other conditions such as metabolic disease known to interfere with the absorption, distribution, metabolism, and excretion of drugs;
- Malignancy, regardless of location;
- Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple sclerosis, rheumatoid arthritis, or sarcoidosis;
- Investigational agents are prohibited one month prior to entry and for the duration of the trial;
- Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);
- Currently taking cromolyn, or have taken cromolyn, within the past 30 days;
- NSAID use (products containing ibuprofen while on study);
- Aspirin, or products containing aspirin, while on study;
- Allergy or hypersensitivity to cromolyn (also known as Intal®, Nasalcrom®, etc.);
- Allergy or hypersensitivity to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin, including Stevens-Johnson syndrome;
- History of hypersensitivity or allergies to any of the drug compound under investigation (cromolyn, ibuprofen, lactose, or magnesium stearate);
- History of clinically significant respiratory disorders and chronic respiratory disease with impaired respiratory effort or difficulty taking inhaled drugs (examples: COPD, emphysema);
- Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC < 70% of the predicted value for the subject, when compared to reference values; AND FEV1 and FVC < 70% of predicted value when compared to reference values, indicating moderate to severe respiratory obstruction;
- Any other disease or condition, which, in the opinion of the investigator, would make the subject unsuitable for this study;
- Female subjects of reproductive potential with a positive pregnancy test (urine or serum) or who are pregnant or lactating.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment A-B
12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other.
All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis.
CSF collected on Day 1 only.
|
Mast cell stabilizer
Other Names:
anti-inflammatory
Other Names:
The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
|
Other: Treatment B-A
12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis.
CSF collected on Day 1 only.
|
Mast cell stabilizer
Other Names:
anti-inflammatory
Other Names:
The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-compartmental plasma pharmacokinetics for ALZT-OP1a and ALZT-OP1b
Time Frame: T=0 to 6 hours (0, 5, 10, 15, 30, 60, 120, 240, and 360 minutes)
|
Plasma concentration-time profiles will be presented for both study drugs. |
T=0 to 6 hours (0, 5, 10, 15, 30, 60, 120, 240, and 360 minutes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of ALZT-OP1a and ALZT-OP1b in cerebrospinal fluid (CSF)
Time Frame: T=0 to 4 hours (0, 5, 30, 120, and 240 minutes)
|
CSF samples will be collected at 5 time-points to measure levels of ALZT-OP1a and ALZT-OP1b in CSF.
|
T=0 to 4 hours (0, 5, 30, 120, and 240 minutes)
|
Number of Treatment Emergent Adverse Events (TEAE)
Time Frame: 2 days
|
Safety will be evaluated based on the number, type, and frequency of treatment emergent adverse events.
They will be individually presented for all subjects in data listings, and summarized in tables by treatment group and by treatment assignment.
The AEs will be summarized and reported collectively based on information obtained through physical examination, ECG, and laboratory findings captured after dosing was initiated.
|
2 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: David Elmaleh, PhD, Study Sponsor
- Study Director: David Brazier, BS, Study Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
- AZT-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on ALZT-OP1a
-
AZTherapies, Inc.APCER Life Sciences; PharmaConsulting Group; KCAS BioCompletedAlzheimer's DiseaseUnited States, Australia, Poland, Czechia, Hungary, Bulgaria, Canada
-
AZTherapies, Inc.TerminatedAmyotrophic Lateral SclerosisUnited States
-
AZTherapies, Inc.CompletedAlzheimer Disease | Healthy VolunteersUnited States